SI-BONE, Inc. Stock Deutsche Boerse AG

Equities

2K3

US8257041090

Medical Equipment, Supplies & Distribution

Market Closed - Deutsche Boerse AG 09:29:01 2024-06-14 am EDT 5-day change 1st Jan Change
11.8 EUR -3.28% Intraday chart for SI-BONE, Inc. -3.28% -37.89%
Sales 2024 * 165M 154M Sales 2025 * 195M 182M Capitalization 522M 487M
Net income 2024 * -39M -36.44M Net income 2025 * -33M -30.83M EV / Sales 2024 * 2.53 x
Net cash position 2024 * 103M 96.31M Net cash position 2025 * 88.22M 82.43M EV / Sales 2025 * 2.23 x
P/E ratio 2024 *
-13.3 x
P/E ratio 2025 *
-16.1 x
Employees 344
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.88%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.28%
1 week-3.28%
Current month-4.07%
1 month-13.87%
3 months-18.06%
6 months-33.71%
Current year-37.89%
More quotes
1 week
11.80
Extreme 11.8
12.20
1 month
11.80
Extreme 11.8
13.80
Current year
11.80
Extreme 11.8
19.90
1 year
11.80
Extreme 11.8
26.00
3 years
10.90
Extreme 10.9
28.00
5 years
10.90
Extreme 10.9
29.40
10 years
10.90
Extreme 10.9
29.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 15-05-25
Founder 69 08-03-17
Director of Finance/CFO 44 21-04-18
Members of the board TitleAgeSince
Founder 69 08-03-17
Director/Board Member 70 12-12-31
Director/Board Member 77 10-12-31
More insiders
Date Price Change
24-06-14 11.8 -3.28%
24-06-13 12.2 +0.83%
24-06-12 12.1 0.00%
24-06-11 12.1 -0.82%
24-06-10 12.2 0.00%

Delayed Quote Deutsche Boerse AG, June 14, 2024 at 09:29 am EDT

More quotes
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
12.66 USD
Average target price
25.56 USD
Spread / Average Target
+101.86%
Consensus